Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 180.09 USD 0.05%
Market Cap: 318.2B USD
Have any thoughts about
Abbvie Inc?
Write Note

Operating Margin
Abbvie Inc

27.8%
Current
33%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.8%
=
Operating Profit
15.4B
/
Revenue
55.5B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Abbvie Inc
NYSE:ABBV
317.4B USD
28%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116.8B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.5B USD
-9%
Country US
Market Cap 317.4B USD
Operating Margin
28%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 141.6B USD
Operating Margin
19%
Country US
Market Cap 116.8B USD
Operating Margin
38%
Country US
Market Cap 105.3B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36.2B EUR
Operating Margin
-22%
Country US
Market Cap 31.5B USD
Operating Margin
-9%
No Stocks Found

Abbvie Inc
Glance View

Market Cap
318.2B USD
Industry
Biotechnology
Economic Moat
Wide

AbbVie Inc., a leader in the pharmaceutical industry, emerged from its parent company Abbott Laboratories in 2013, with a mission centered around addressing some of the world’s most complex and serious diseases. At its core, AbbVie is a research-driven entity that leverages scientific innovation to develop advanced therapies. With a robust pipeline, the company focuses on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, and women's health. It has developed a diversified portfolio designed to tackle challenging health issues. The company devotes significant resources to research and development, fostering a culture that celebrates scientific discovery as a pathway to improving patient lives worldwide. Revenue generation for AbbVie is deeply intertwined with its treatment offerings, particularly its lineup of blockbuster drugs. The flagship product, Humira, an anti-inflammatory medication, has consistently stood as one of the top-selling drugs globally. Despite facing patent expirations for Humira, AbbVie has strategically navigated this challenge through its robust product pipeline, which includes promising medicines like Skyrizi and Rinvoq in immunology. The company also expanded its revenue potential significantly with the acquisition of Allergan in 2020, adding Botox and other products in aesthetics and eye care to its portfolio. The calculated diversification of revenue streams ensures AbbVie maintains a competitive edge, securing its position as a formidable player in the pharmaceutical industry.

ABBV Intrinsic Value
147.11 USD
Overvaluation 18%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.8%
=
Operating Profit
15.4B
/
Revenue
55.5B
What is the Operating Margin of Abbvie Inc?

Based on Abbvie Inc's most recent financial statements, the company has Operating Margin of 27.8%.